bioAffinity Technologies, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Maria Zannes
- Full Time Employees
- 57
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 3300 Nacogdoches Road San Antonio TX United States of America 78217
- IPO Date
- Sep 1, 2022
- CIK
- 0001712762
- Website
- bioaffinitytech.com
- Similar Companies
- Business
- bioAffinity Technologies, Inc. (NASDAQ: BIAF) develops noninvasive diagnostics for early-stage lung cancer and other lung diseases using flow cytometry and automated analysis; it also advances targeted cancer therapeutics through its subsidiary OncoSelect Therapeutics. The company offers CyPath Lung, a laboratory-developed test that analyzes sputum samples with a porphyrin molecule to detect cancer cells via fluorescence, marketed through its wholly owned subsidiary Precision Pathology Laboratory Services, LLC (PPLS) to high-risk patients following suspicious low-dose CT findings; additional pipeline efforts target diagnostics for other cancers and lung conditions like COPD via porphyrin-based flow cytometry, alongside broad-spectrum therapeutics that selectively kill cancer cells in preclinical stages. Founded in 2014 and headquartered in San Antonio, Texas, bioAffinity Technologies operates in the United States within the biotechnology and in vitro diagnostics industry, serving physicians, veterans' healthcare, and high-risk patient populations. In September 2023, the company acquired PPLS, boosting 2024 laboratory revenues toward $9.4 million with over 20% annualized growth and a 1,750% rise in CyPath Lung sales through November versus the prior year; recent achievements include securing reimbursement for CyPath Lung, gaining federal healthcare access, expanding the sales team, and streamlining operations ahead of national market rollout; bioAffinity closed a $4.8 million public offering in September 2025 via WallachBeth Capital to fund technology development.
Company News
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules